Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non-Lean Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease-Authors' Reply [0.03%]
编辑来信：对代谢功能异常相关肝脂肪变性疾病的瘦型和非瘦型患者进行同等程度的纤维化风险监测作者回信
Kaleb Tesfai,Luis Antonio Díaz,Veeral Ajmera
Kaleb Tesfai
Letter on 'Unveiling Drug-Induced Autoimmune-Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study' [0.03%]
关于“揭开自身免疫性肝炎患者药物诱发的自身免疫性肝炎：一项多中心回顾性研究”的信件
Muhammad Ibrahim Khalil,Kashafaduja Be Fatima,Aleena Zafar
Muhammad Ibrahim Khalil
Letter on 'Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis' [0.03%]
关于“奥贝胆酸无应答与原发性胆汁性胆管炎临床事件风险增加有关”的信件
Yi Pei,Runze Jiang,Shenglong Li
Yi Pei
Review Article: The Evolving Role of GLP-1 Receptor Agonists in Gastroenterology Practice [0.03%]
综述：GLP-1受体激动剂在胃肠病学实践中的作用演变
Sydney Pomenti,Annabel Gerber,David Katzka et al.
Sydney Pomenti et al.
Background: Obesity affects over 40% of the US population and contributes to worse outcomes in a variety of diseases and disorders. Glucagon-like peptide-1 receptor agonists have drawn attention for their impact on obesit...
A Population-Based Matched Cohort Study of Extra-Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease [0.03%]
基于人群的匹配队列研究：炎症性肠病患者和非炎症性肠病患者的肠外癌症发病率和死亡率
Sanjay K Murthy,Faria Ahmed,Michael Pugliese et al.
Sanjay K Murthy et al.
Background: Trends in extra-digestive (ED) cancer incidence and mortality in inflammatory bowel diseases (IBD) may be changing with newer approaches to management. ...
Letter: Refining Mortality Estimates in Severe Alcohol-Associated Hepatitis-Addressing Heterogeneity and Prognostic Assessment [0.03%]
来信：严重酒精相关性肝炎预后评估和异质性分析致死率估计的完善
Shupeng Zhao,Leilei Zhai,Ping Yao
Shupeng Zhao
Letter: Refining Mortality Estimates in Severe Alcohol-Associated Hepatitis-Addressing Heterogeneity and Prognostic Assessment. Authors' Reply [0.03%]
致编辑关于严重酒精性肝炎患者死亡率估计的来信及作者回复：解决异质性和预后评估的问题
Francisco Idalsoaga,Luis Antonio Diaz,Mohammad Qasim Khan et al.
Francisco Idalsoaga et al.
Indocyanine Green Clearance Correlates With Biomarkers Reflecting Key Disease-Driving Mechanisms in Advanced Chronic Liver Disease and Predicts Acute-on-Chronic Liver Failure and Death [0.03%]
吲哚菁绿清除与晚期慢性肝病的关键病理生理机制相关，并可预测急性-on-慢性肝功能衰竭和死亡的风险
Mathias Jachs,Tânia Carvalho,Benedikt Simbrunner et al.
Mathias Jachs et al.
Background: Indocyanine green (ICG) clearance, determined by venous sampling, has shown promising results in the diagnosis of clinically significant portal hypertension (CSPH) in compensated advanced chronic liver disease...
Letter: Safety and Tolerability of Injectable Extended Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol-Associated Liver Disease [0.03%]
纳曲酮注射液治疗酒精性肝病伴酒精使用障碍的安全性和耐受性：来信
Xing Bai,Ziqi Sui,Yunmeng Nie
Xing Bai
Letter: Safety and Tolerability of Injectable Extended-Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol-Associated Liver Disease-Authors' Reply [0.03%]
致编辑关于长效注射用缓释纳曲酮在晚期酒精性肝病患者中治疗酒精使用障碍的安全性和耐受性的作者回信
Luis Antonio Díaz,Rohit Loomba
Luis Antonio Díaz